当43岁主持人金昀骤然离世的新闻刷屏，一个陌生医学术语引发公众关注——​​肺动脉高压（PH）​​。这种被称作"心肺桥梁崩塌"的疾病，每年吞噬数十万生命。想象一下，身体里有一根连接心脏和肺脏的“生命管道”，负责把全身缺氧的血液送到肺部去“充氧”。如果这 ...

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.

肺动脉高压是一种以肺动脉压力持续升高为特征的严重肺血管疾病，临床上，常用血管舒张剂来缓解症状和降低血流阻力，但针对肺血管重塑这一病变核心环节，目前尚缺乏有效的治疗手段。免疫疗法作为近年来兴起的重要治疗策略，逐渐显示出在肺动脉高压治疗中的潜力。

未经治疗的中重度肺动脉高压患者的五年生存率低于50%，这一数据凸显了及时诊断和积极治疗的重要性。肺动脉高压的高死亡率主要归因于疾病的进展性和复杂性。患者需要长期接受治疗，并且需要定期监测和调整治疗方案。此外，高昂的医疗费用和心理压力也是患者面临的重要挑战。

Among patients with pulmonary arterial hypertension, once-daily treprostinil palmitil inhalation powder for 16 weeks reduced ...

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

Phase 3 study results evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension were announced.

Roivant Sciences Ltd. (NASDAQ: ROIV) is one of the best biotech stocks to invest in now. On June 16, Pulmovant, a Roivant ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the conclusion of enrollment of the phase 3 ADVANCE OUTCOMES study evaluating the use of an extended-release ...

In PAH, pulmonary rehabilitation referral and participation rates are low and are significantly affected by demographic and socioeconomic factors.